4-丁基苯铵氯化物 | 13478-63-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-丁基苯铵氯化物
• 英文名称: p-butylaniline hydrochloride
• 英文别名: 4-butylanilinium chloride；4-butylaniline hydrochloride；4-Butylaniline--hydrogen chloride (1/1)；4-butylaniline;hydrochloride
• CAS: 13478-63-2
• 化学式: C₁₀H₁₆N*Cl
• 分子量: 185.697
• InChiKey: KGVOSBWDKAXACO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.09
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  27.6
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2923900090

反应信息

• 作为反应物：
  描述：

  4-丁基苯铵氯化物 以 甲苯 为溶剂， 生成 3-{4-[1-(2,3-Dihydro-1H-inden-2-yl)-3-(4-butylphenyl)ureidomethyl]benzoylamino)propionic Acid
  参考文献：
  名称：

  New β-Alanine Derivatives Are Orally Available Glucagon Receptor Antagonists

  摘要：

  A weak human glucagon receptor antagonist with an IC50 of 7 mu M was initially found by screening of libraries originally targeted to mimic the binding of the glucagon-like peptide (GLP-1) hormone to its receptor. Optimization of this hit for binding affinity for the glucagon receptor led to ligands with affinity in the nanomolar range. In addition to receptor binding, optimization efforts were made to stabilize the molecules against fast metabolic turnover. A potent antagonist of the human human glucagon receptor was obtained that had 17% oral availability in rats with a plasma half-life of 90 min. The major metabolites of this lead were identified and used to further optimize this series with respect to pharmacokinetic properties. This final optimization led to a potent glucagon antagonist that was orally available in rats and dogs and was efficacious in lowering blood glucose levels in a diabetic animal model.

  DOI：

  10.1021/jm058026u
• 作为试剂：
  描述：

  2-溴次黄嘌呤 在 palladium on activated charcoal 氢气 、 sodium hydride 、 potassium carbonate 、 4-丁基苯铵氯化物 、 N,N-二甲基苯胺 、 三氯氧磷 作用下， 以 乙醇 、 乙二醇甲醚 为溶剂， 25.0 ℃ 、344.73 kPa 条件下， 反应 13.0h， 生成 2-[[2-(4-丁基苯胺基)嘌呤-9-基]甲氧基]乙醇
  参考文献：
  名称：

  2-（pn-丁基苯胺基）嘌呤及其核苷类似物的合成，细胞生长抑制和抗肿瘤筛选。

  摘要：

  合成了N2-（pn-丁基苯基）鸟嘌呤（BuPG）和2-（pn-丁基苯胺基）腺嘌呤（BuAA）的衍生物，并测试了它们作为哺乳动物DNA聚合酶α，细胞生长和大分子合成的抑制剂。2-（pn-Butylanilino）-6-氯嘌呤（BuACl）用作制备一系列6取代类似物的有用中间体。BuACl的钠盐与2-乙氧基3,5-二-对甲苯甲酰基-β-D-呋喃呋喃糖基氯在乙腈中反应，得到64％的相应9-β核苷（封端的BuAdCl）和仅14％ 7-β异构体 在BuAdCl中对氯进行解封和取代生成了一系列2-（pn-丁基苯胺基）-9-（2-脱氧-β-D-核呋喃糖基）嘌呤衍生物。解封并取代6-氯基团后，BuACl的钠盐与（2-乙酰氧基乙氧基）甲基溴反应，一系列的2-（pn-丁基苯胺基）-9-[（2-羟基乙氧基）甲基]嘌呤。合成的碱基是从中国仓鼠卵巢细胞中分离的DNA聚合酶α的抑制剂，最有效的化合物是2-（pn-丁基

  DOI：

  10.1021/jm00384a019

文献信息

• Improved Procedures for the Preparation of Cycloalkyl-, Arylalkyl-, and Arylthioureas
  作者：C. R. Rasmussen、F. J. Villani, Jr.、L. E. Weaner、B. E. Reynolds、A. R. Hood、L. R. Hecker、S. O. Nortey、A. Hanslin、M. J. Costanzo、E. T. Powell、A. J. Molinari

  DOI：10.1055/s-1988-27605

  日期：——

  An improved procedure for the preparation of arylthioureas consists of the reaction of benzoyl isothiocyanate with anilines in acetone and debenzoylation of the resultant N-aryl-N′-benzoylthioureas with 5% aqueous sodium hydroxide. Bicycloalkylthioureas and N-(arylalkyl)thioureas (e.g., 9H-9-fluorenylthiourea) are directly prepared from the corresponding isothiocyanates and ammonia.

  制备芳基硫脲的改进方法包括将苯甲酰异硫氰酸酯与苯胺在丙酮中反应，然后用5%氢氧化钠水溶液对生成的N-芳基-N'-苯甲酰硫脲进行去苯甲酰化。双环烷基硫脲和N-(芳烷基)硫脲（例如9H-9-芴基硫脲）可直接由相应的异硫氰酸酯与氨反应制备。
• The Landscape of the Anti-Kinase Activity of the IDH1 Inhibitors
  作者：Katarzyna Malarz、Jacek Mularski、Marcin Pacholczyk、Robert Musiol

  DOI：10.3390/cancers12030536

  日期：——

  Isocitrate dehydrogenases constitute a class of enzymes that are crucial for cellular metabolism. The overexpression or mutation of isocitrate dehydrogenases are often found in leukemias, glioblastomas, lung cancers, and ductal pancreatic cancer among others. Mutation R132H, which changes the functionality of an enzyme to produce mutagenic 2-hydroxyglutarate instead of a normal product, is particularly important in this field. A series of inhibitors were described for these enzymes of which ivosidenib was the first to be approved for treating leukemia and bile duct cancers in 2018. Here, we investigated the polypharmacological landscape of the activity for known sulfamoyl derivatives that are inhibitors, which are selective towards IDH1 R132H. These compounds appeared to be effective inhibitors of several non-receptor kinases at a similar level as imatinib and axitinib. The antiproliferative activity of these compounds against a panel of cancer cells was tested and is explained based on the relative expression levels of the investigated proteins. The multitargeted activity of these compounds makes them valuable agents against a wide range of cancers, regardless of the status of IDH1.

  异柠檬酸脱氢酶是一类对细胞代谢至关重要的酶。异柠檬酸脱氢酶的过表达或突变常见于白血病、胶质母细胞瘤、肺癌和导管性胰腺癌等疾病中。突变R132H可改变酶的功能，产生致突变性的2-羟基戊二酸，而非正常产物，这在该领域尤为重要。已描述了一系列针对这些酶的抑制剂，其中ivosidenib是2018年首个获批用于治疗白血病和胆管癌的药物。我们研究了已知磺胺基衍生物的多药效活性，这些抑制剂对IDH1 R132H具有选择性。这些化合物显示出对几种非受体激酶的有效抑制作用，水平与伊马替尼和阿希替尼相似。对这些化合物在一系列癌细胞中的抗增殖活性进行了测试，并根据所研究蛋白质的相对表达水平进行了解释。这些化合物的多靶活性使它们成为抗多种癌症的有价值药物，不受IDH1状态的影响。
• Quinazoline derivatives and therapeutic use thereof
  申请人：Lee B. Young

  公开号：US20050187231A1

  公开（公告）日：2005-08-25

  Quinazoline derivatives represented by the general formula pharmacologically acceptable salts thereof, and compositions containing such compounds are described. Methods for using the compounds for treatment of hyperproliferative disorders are also described.

  描述了由一般式表示的喹唑啉衍生物及其药理学可接受的盐，以及含有这些化合物的组合物。还描述了使用这些化合物治疗过度增生性疾病的方法。
• Phosphorus pentoxide in organic synthesis. XX. Synthesis of<i>N</i>-aryl-7<i>H</i>-pyrrolo[2,3-d]pyrimidin-4-amines
  作者：Anker Jørgensen、Khairy A. M. El-Bayouki、Erik B. Pedersen

  DOI：10.1002/jhet.5570220351

  日期：1985.5

  N-Aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines 7 were prepared in 30-67% yields by treating N7-(1-phenyl-ethyl)pyrrolo[2,3-d]pyrimidin-4(3H)-ones 2 with a mixture of phosphorus pentoxide, triethylamine hydrochloride, and an appropriate arylamine hydrochloride at 240° for 3-7 hours.

  ñ -芳基- 7 ħ吡咯并[2,3- d ]嘧啶-4-胺7在30-67％的收率通过处理N7-（1-苯基-乙基）吡咯并[2,3制备d ]嘧啶4（3 H）-ones 2与五氧化二磷，三乙胺盐酸盐和适当的芳基胺盐酸盐的混合物在240°C搅拌3-7小时。
• Two-dimensional antiferromagnetism and weak ferromagnetism in some anilinium salts of the types A2MnCl4 and A2FeCl4
  作者：Antony B. Blake、William E. Hatfield

  DOI：10.1039/dt9790001725

  日期：——

  resulting magnetisation lies in the layer plane. Powder susceptibility measurements on (4-ClC6H4NH3)2FeCl4 indicate that this compound is also a two-dimensional antiferromagnet, with –J/k= 10.7 ± 0.5 K (TNca. 87 K) and a canting angle ca. 0.8° in the ordered state. Below TN the magnetic behaviour shows unusual dependence on the thermal and magnetic history of the sample, possibly due to a nearly degenerate

  对粉状盐（4-XC 6 H 4 NH 3）2 MnCl 4（X = F，Cl，Br或Bu n）进行的磁化率测量为4.2至160K 。这些化合物具有K 2 NiF 4类型的层结构，层间距分别为15.8、16.6、18.8和23.5。大约在600 ℃观察到了最大的磁化率最大值。70 K，并且可以被安装在海森堡的二维交换作用的假设（-2 Ĵ小号我：S Ĵ）形式，具有- Ĵ / ķ分别为4.25、4.50、4.00和3.75（±0.1）K。所有四种化合物显示低于奈耳温度（弱铁磁性Ť Ñ约40 K），这归因于旋转斜在反铁磁有序状态。转变温度实际上与层间距无关。在4-氯化合物的单晶上进行的测量表明，倾斜角为约3 ° 。0.06°，并表明产生的磁化强度位于层平面中。在（4-ClC 6 H 4 NH 3）2 FeCl 4上的粉末磁化率测量表明，该化合物也是二维反铁磁体，具有– J / k= 10.7±0.5